SCHEMBL3429172

SCHEMBL3429172

COc1cccc2c1C(Nc1ccc3cc(NC(=O)NC4CCN(C5CC5)CC4)ccc3n1)CCC2

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 2/20 0.44
KMT2A Q03164 2/20 0.42
MEN1 O00255 1/20 0.42
ALDH1A1 P00352 1/20 0.42
MAPT P10636 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.39
NPSR1 Q6W5P4 1/20 0.39
RAB9A P51151 1/20 0.39
DRD2 P14416 3/20 0.38
ADRA1D P25100 3/20 0.38
ADRA1A P35348 3/20 0.38
ADRA1B P35368 3/20 0.38
EPHX2 P34913 1/20 0.38
UBE2M P61081 1/20 0.37
DCUN1D1 Q96GG9 1/20 0.37
CCNC P24863 1/20 0.37
CDK8 P49336 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3414587 0.95 SMN1; SMN2 (0.40) NPC1SMN1; SMN2NPSR1RAB9ADRD2
SCHEMBL3430017 0.93 NPC1 (0.45) NPC1KMT2AMEN1ALDH1A1MAPT
SCHEMBL3415077 0.90 NPC1 (0.44) NPC1KMT2AMEN1ALDH1A1MAPT
SCHEMBL3432219 0.90 NPC1 (0.44) NPC1KMT2AMEN1ALDH1A1MAPT
SCHEMBL3432212 0.90 NPC1 (0.44) NPC1KMT2AMEN1ALDH1A1MAPT
SCHEMBL3433103 0.90 NPC1 (0.44) NPC1KMT2AMEN1ALDH1A1MAPT
SCHEMBL3406470 0.88 SMN1; SMN2 (0.46) NPC1KMT2AMEN1ALDH1A1MAPT
SCHEMBL3410235 0.88 SMN1; SMN2 (0.46) NPC1KMT2AMEN1ALDH1A1MAPT
SCHEMBL3412100 0.88 SMN1; SMN2 (0.43) NPC1SMN1; SMN2NPSR1RAB9AEPHX2
SCHEMBL3431355 0.88 NPC1 (0.45) NPC1KMT2AMEN1ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US claimed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP claimed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO claimed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US claimed
US-8183380-B2 2-aminoquinolines HOFFMANN-LA ROCHE INC. (US) 2012-05-22 US disclosed
EP-2262789-A1 2-AMINOQUINOLINES F. Hoffmann-La Roche AG (CH) 2010-12-22 EP disclosed
WO-2009109477-A1 2-AMINOQUINOLINES F. HOFFMANN-LA ROCHE AG (CH) 2009-09-11 WO disclosed
US-20090227570-A1 2-AMINOQUINOLINES HOFFMANN-LA ROCHE, INC. 2009-09-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090227570-A1 2-AMINOQUINOLINES HTR5A, HTR2C, HTR2A NPC1 2931/4885KMT2A 822/4885MEN1 1524/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.